Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity Yong Ling Xiaolei Ye Zhenzhen Zhang Yihua Zhang Yisheng Lai Hui Ji Sixun Peng Jide Tian 10.1021/jm1014814.s001 https://acs.figshare.com/articles/journal_contribution/Novel_Nitric_Oxide_Releasing_Derivatives_of_Farnesylthiosalicylic_Acid_Synthesis_and_Evaluation_of_Antihepatocellular_Carcinoma_Activity/2653342 Novel furoxan-based nitric oxide (NO) releasing derivatives (<b>8a</b>–<b>p</b>) of farnesylthiosalicylic acid (FTS) were synthesized. Compound <b>8l</b> displayed the strongest inhibition on the proliferation of human hepatocellular carcinoma (HCC) cells in vitro, superior to FTS, sorafenib, and furoxan moiety, selectively induced high frequency of HCC cell apoptosis, and produced high levels of NO in HCC cells but not in nontumor liver cells. Furthermore, <b>8l</b> exhibited low acute toxicity to mice and significantly inhibited the growth of HCC tumors in vivo and the Ras-related signaling in the tumors. Therefore, our novel findings may provide a new framework for the design of new NO-releasing furoxan/FTS hybrids for the intervention of human HCC. 2011-05-12 00:00:00 FTS nontumor liver cells Compound 8 l HCC tumors novel findings HCC cells furoxan moiety HCC cell apoptosis 8 l farnesylthiosalicylic acid hepatocellular carcinoma